April 11, 2017—The U.S. Preventive Services Task Force seeks comments on a draft recommendation statement and draft evidence reviews on screening for prostate cancer. Based on a review of the evidence, the Task Force determined that the potential benefits and harms of prostate-specific antigen (PSA)–based screening are closely balanced in men ages 55 to 69 years, and that the decision about whether to be screened should be an individual one. For men age 70 years and older, the potential benefits do not outweigh the harms, and these men should not be screened for prostate cancer. The draft recommendation statement and draft evidence reviews are available for review and public comment from April 11 through May 8, 2017.
For more information about these draft recommendations and to submit comments, go to www.
In addition to posting the draft materials, the Task Force has developed answers to frequently asked questions, a fact sheet, and an infographic to help health care professionals, stakeholders, and the public understand and communicate about these draft recommendations. They are available at www.Public Comment on Draft Recommendation Statement: Screening for Prostate Cancer